Scribe Therapeutics filed for a Nasdaq IPO, setting up a liquidity event for the clinical-stage CRISPR enzyme developer as investors assess demand for early gene-editing exposure. The filing marks another potential listing pathway for platform and enzyme-centric genome editing companies that are trying to translate technical progress into clinical de-risking. The move comes amid active fundraising and deal flow across the sector, with markets increasingly responsive to clear clinical signals and scalable intellectual property in gene editing. For Scribe, the IPO process will sharpen focus on trial readouts, manufacturability and regulatory strategy, which are central to the valuation debate for personalized and precision genome-editing platforms.